{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:35:15Z","timestamp":1795041315423,"version":"4.10.2"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3605400"],"award-info":[{"award-number":["2023YFC3605400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lecanemab is a newly approved monoclonal antibody targeting amyloid plaques for the treatment of early Alzheimer\u2019s disease. This study aimed to evaluate the safety and short-term biomarkers and cognition changes of lecanemab in Chinese clinical practice.<\/jats:p>\n                  <jats:p>This multicentre real-world study involved patients receiving lecanemab treatment across seven hospitals in China. Patients underwent comprehensive assessments before treatment. Lecanemab was administered via intravenous infusion every 2 weeks. Treatment-related symptoms were monitored through self-report, and amyloid-related imaging abnormalities were assessed via magnetic resonance imaging. Amyloid and tau biomarker changes were measured using positron emission tomography imaging or plasma testing. Follow-up cognitive assessments were evaluated after 6 months of treatment. Short-term outcomes were analysed using linear mixed-effect models, without an untreated control group.<\/jats:p>\n                  <jats:p>A total of 407 patients who received at least one lecanemab infusion were involved in this study, with a mean follow-up time of 5.6 \u00b1 3.39 months. The mean age was 68.08 years, with 67.57% of patients being female. Of the participants, 56.51% were apolipoprotein E (APOE) \u03b54 carriers, and 83.19% were at biological Stage C. During the study period, 22.22% of the patients experienced treatment-related symptoms, and 12.15% developed at least one amyloid-related imaging abnormality. Only four symptomatic and seven severe amyloid-related imaging abnormality cases were reported. APOE \u03b54 status was not related to adverse events in the Chinese population. Patients with a higher number of microhaemorrhages at baseline were more likely to develop adverse events. No significant differences in adverse events were observed between the moderate Alzheimer\u2019s disease dementia group and the mild cognitive impairment group. By the end of the research period, 9.38% of the patients withdrew from lecanemab. After 6 months of treatment, favourable short-term outcomes in biomarkers and stable cognitive function were observed.<\/jats:p>\n                  <jats:p>This study demonstrates that lecanemab treatment is feasible and well-tolerated among the Chinese population, with lower rates of adverse events and favourable short-term outcomes observed. Administration of lecanemab in the moderate Alzheimer\u2019s disease dementia population was relatively safe and further studies are warranted.<\/jats:p>","DOI":"10.1093\/brain\/awaf427","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:34:15Z","timestamp":1762778055000},"page":"1973-1985","source":"Crossref","is-referenced-by-count":18,"title":["Safety and short-term outcomes of lecanemab for Alzheimer\u2019s disease in China: a multicentre study"],"prefix":"10.1093","volume":"149","author":[{"given":"Ling-Ling","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Ze","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]},{"name":"Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University , Fuzhou 350402 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5671-3902","authenticated-orcid":false,"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou 325000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Soochow University , Soochow 215004 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Qingdao Municipal Hospital Group , Qingdao 266000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanjing First Hospital, Nanjing Medical University , Nanjing 210006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310031 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Liang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310031 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310031 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Yong","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University , Fuzhou 350402 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Zhao","family":"Ju","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University , Shanghai 200433 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Huashan Hospital, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Third Hospital of Hebei Medical University , Hebei 050051 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Huashan Hospital, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8856-7217","authenticated-orcid":false,"given":"Chuan-Tao","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University , Shanghai 200433 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanjing First Hospital, Nanjing Medical University , Nanjing 210006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Qingdao Municipal Hospital Group , Qingdao 266000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University , Fuzhou 350402 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Hua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ping","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310031 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wei","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University , Fuzhou 350402 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7686-0547","authenticated-orcid":false,"given":"Jin-Tai","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University , Shanghai 200040 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2026060310564913900_awaf427-B1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur J Neurol"},{"key":"2026060310564913900_awaf427-B2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"key":"2026060310564913900_awaf427-B3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","article-title":"Lecanemab: First approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"2026060310564913900_awaf427-B4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2026060310564913900_awaf427-B5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamaneurol.2023.3599","article-title":"APOE genotype and Alzheimer disease risk across age, sex, and population ancestry","volume":"80","author":"Belloy","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026060310564913900_awaf427-B6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132021: A systematic analysis for the global burden of disease study 2021","volume":"23","author":"GBD 2021 Stroke Risk Factor Collaborators","year":"2024","journal-title":"Lancet Neurol"},{"key":"2026060310564913900_awaf427-B7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","article-title":"Amyloid-related imaging abnormalities: Manifestations, metrics and mechanisms","volume":"21","author":"Greenberg","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"2026060310564913900_awaf427-B8","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/STR.0000000000000480","article-title":"Vascular neurology considerations for antiamyloid immunotherapy: A science advisory from the American Heart Association","volume":"56","author":"Greenberg","year":"2025","journal-title":"Stroke"},{"key":"2026060310564913900_awaf427-B9","doi-asserted-by":"crossref","first-page":"100160","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer\u2019s disease","volume":"12","author":"Chen","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"2026060310564913900_awaf427-B10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1037\/pag0000032","article-title":"Effects of education and race on cognitive decline: An integrative study of generalizability versus study-specific results","volume":"30","author":"Gross","year":"2015","journal-title":"Psychol Aging"},{"key":"2026060310564913900_awaf427-B11","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026060310564913900_awaf427-B12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2026060310564913900_awaf427-B13","doi-asserted-by":"crossref","first-page":"S673","DOI":"10.1016\/j.ijrobp.2011.06.929","article-title":"Common terminology criteria for adverse events (CTCAE) v4.0 based hybrid patient and physician questionnaire for head and neck (HN) radiotherapy symptom reporting","volume":"81","author":"Gay","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026060310564913900_awaf427-B14","author":"Administration UFaD","year":"2025"},{"key":"2026060310564913900_awaf427-B15","doi-asserted-by":"crossref","first-page":"118775","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data","volume":"246","author":"Iaccarino","year":"2022","journal-title":"Neuroimage"},{"key":"2026060310564913900_awaf427-B16","first-page":"266","article-title":"Standardization of amyloid quantitation with 18F-florbetapir SUV ratio to the centiloid scale and its application in Chinese preclinical Alzheimer\u2019s disease study","volume":"44","author":"Huang","year":"2024","journal-title":"Chin J Nucl Med Mol Imaging"},{"key":"2026060310564913900_awaf427-B17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuroimage.2017.04.035","article-title":"Freesurfer cortical normative data for adults using Desikan-Killiany-Tourville and ex vivo protocols","volume":"156","author":"Potvin","year":"2017","journal-title":"Neuroimage"},{"key":"2026060310564913900_awaf427-B18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer\u2019s association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2026060310564913900_awaf427-B19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026060310564913900_awaf427-B20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10654-024-01144-2","article-title":"Incidence and prevalence of Alzheimer\u2019s disease in China: A systematic review and meta-analysis","volume":"39","author":"Ji","year":"2024","journal-title":"Eur J Epidemiol"},{"key":"2026060310564913900_awaf427-B21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamainternmed.2023.1749","article-title":"Estimated annual spending on lecanemab and its ancillary costs in the US medicare program","volume":"183","author":"Arbanas","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2026060310564913900_awaf427-B22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026060310564913900_awaf427-B23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center","volume":"11","author":"Shields","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"2026060310564913900_awaf427-B24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00415-025-13142-9","article-title":"Monoclonal antibody administration in an academic institution and private neurological practice: A tale of two clinics","volume":"272","author":"Rosenbloom","year":"2025","journal-title":"J Neurol"},{"key":"2026060310564913900_awaf427-B25","doi-asserted-by":"crossref","first-page":"1561020","DOI":"10.3389\/fphar.2025.1561020","article-title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases","volume":"16","author":"Hu","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026060310564913900_awaf427-B26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"2026060310564913900_awaf427-B27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"2026060310564913900_awaf427-B28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: A systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026060310564913900_awaf427-B29","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1002\/alz.13128","article-title":"APOE \u025b4\u2019s impact on response to amyloid therapies in early symptomatic Alzheimer\u2019s disease: Analyses from multiple clinical trials","volume":"19","author":"Evans","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2026060310564913900_awaf427-B30","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaneurol.2025.1100","article-title":"Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease","volume":"82","author":"Pichet Binette","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026060310564913900_awaf427-B31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"2026060310564913900_awaf427-B32","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: A secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026060310564913900_awaf427-B33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: The TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026060310564913900_awaf427-B34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(02)00236-3","article-title":"Practice effects on cognitive tasks: A major problem?","volume":"1","author":"Wesnes","year":"2002","journal-title":"Lancet Neurol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf427\/65267581\/awaf427.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/6\/1973\/65267581\/awaf427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/6\/1973\/65267581\/awaf427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:56:55Z","timestamp":1780498615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/149\/6\/1973\/8320297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf427","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,11,11]]}}}